Improved Infrastructure Supporting Investigational New Drug Clinical Studies Stressed

While the number of Investigational New Drug (IND) applications has been steadily rising over the past few years, the necessary infrastructure for conducing their clinical studies is grossly inadequate as compared to the international standards, according to a report released by the Samsung Economic Research Institute (SERI).

The SERI’s senior research officer Ko Yu-sang stated that, while t...